Wockhardt: Zaynich leads the next growth phase
Wockhardt Limited is pursuing a transition from a traditional pharmaceutical portfolio towards a research-led specialty pharma and biotechnology model. The long-term opportunity centres on novel antibiotic Zaynich, insulin and biosimilars,…























